

INFINITY PHARMACEUTICALS, INC.  
Form SC 13G/A  
February 10, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2  
(Amendment No. 2)\***

**Infinity Pharmaceuticals, Inc.**

**(Name of Issuer)**

**Common Stock, par value \$0.001 per share**

**(Title of Class of Securities)**

**45665G303**

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form SC 13G/A

(CUSIP Number)

March 28, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

1. NAMES OF REPORTING PERSONS

Amgen Inc.

2. CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP (see instructions)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

-0-

SHARES

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

-0-

EACH

7. SOLE DISPOSITIVE POWER

REPORTING

PERSON

-0-

WITH

8. SHARED DISPOSITIVE POWER

-0-

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

-0-

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

-0-%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

CUSIP No. 45665G303

13G

Page 3 of 5 Pages

**Item 1(a). Name of Issuer:**

Infinity Pharmaceuticals, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**

780 Memorial Drive

Cambridge, MA 02139

**Item 2(a). Name of Person Filing:**

Amgen Inc.

**Item 2(b). Address of Principal Business Office or, if none, Residence:**

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

**Item 2(c). Citizenship:**

Delaware

**Item 2(d). Title of Class of Securities:**

Common stock, par value \$0.001 per share

**Item 2(e). CUSIP Number:**

45665G303

**Item 3. Not applicable.**

**Item 4. Ownership.**

(a) Amount beneficially owned: -0-

- (b) Percent of class:
- (c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote -0-

(ii) Shared power to vote or to direct the vote -0-

(iii) Sole power to dispose or to direct the disposition of -0-

(iv) Shared power to dispose or to direct the disposition of -0-

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certifications.**

Not Applicable



CUSIP No. 45665G303

**13G  
SIGNATURE**

**Page 5 of 5 Pages**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 9, 2009

AMGEN INC.

By: /s/ David J. Scott

Name: David J. Scott

Title: Senior Vice President, General Counsel and  
Secretary